Hazlett, Burt & Watson’s Royalty Pharma RPRX Stock Holding History

Hazlett, Burt & Watson’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10	Closed	–	–	708
2023 Q1	$0	Buy	+10	New	+$371	﹤0.01%	678

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hazlett, Burt & Watson's RPRX Position: Q2 2023 in Review

Hazlett, Burt & Watson sold out of Royalty Pharma (RPRX) in Q2 2023, closing a stake of 10 shares.

Hazlett, Burt & Watson first reported a position in RPRX in Q1 2023 and held it in 1 quarter. The position peaked at $0 in Q1 2023. 325 funds tracked by Wall St. Rank hold RPRX as of Q2 2023.

Hazlett, Burt & Watson reported no remaining Royalty Pharma position as of Q2 2023 after selling out during the quarter.
Hazlett, Burt & Watson sold 10 Royalty Pharma shares in Q2 2023.
Hazlett, Burt & Watson first reported a position in Royalty Pharma in Q1 2023 and held it in 1 quarter.
Hazlett, Burt & Watson's Royalty Pharma position peaked at $0 in Q1 2023.
325 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2023.

Based on Hazlett, Burt & Watson's 13F filing for Q2 2023, filed 1 Aug 2023.